c-Kit receptor (CD117) is expressed by erythroid, megakaryocytic, and myeloid precursors and mature mast cells and has been reported to be expressed in CD30 þ lymphomas such as Hodgkin's disease and anaplastic large-cell lymphoma. Imatinib mesylate, a well-established inhibitor of bcr-abl tyrosine kinase, and currently used for the treatment of patients with chronic myeloid leukemia, also inhibits c-kit receptor kinase activity. In view of the possible use of imatinib as experimental therapy for patients with c-kit-positive tumors, we assessed c-kit expression in CD30 þ cell lines and lymphomas. The cell lines were assessed using multiple methods (RT-PCR, flow cytometry, and Western blot). c-Kit expression was also immunohistochemically assessed in 168 CD30 þ lymphomas including 87 classical Hodgkin's disease, 63 anaplastic large-cell lymphoma, and 15 cutaneous anaplastic large-cell lymphoma. We also studied 18 cases of lymphomatoid papulosis, a CD30 þ lesion closely related to cutaneous anaplastic large-cell lymphoma. Neither c-kit mRNA nor protein was detected in any of the cell lines assessed. Furthermore, treatment with imatinib did not inhibit proliferation of cell lines in vitro. Using immunohistochemistry, only one of 183 (0.5%) lesions was positive for c-kit, the positive case being an ALK-negative anaplastic large-cell lymphoma. Our data demonstrate that expression of c-kit receptor is exceedingly rare among CD30 þ lymphomas and lymphomatoid papulosis, suggesting that ckit receptor is unlikely to be an appropriate target for therapeutic options such as imatinib in patients with these tumors.
The c-kit gene, first identified as the human analog of v-kit, the oncogene of HZ4 feline sarcoma virus, encodes a 145 kDa transmembrane glycoprotein capable of autophosphorylation on tyrosine residues. c-Kit receptor (CD117), henceforth referred to as c-kit in this study, is structurally related to the receptors for macrophage growth factor and platelet-derived growth factor. 1 c-Kit ligand, also known as stem cell factor (SCF), is capable of promoting cell proliferation of both myeloid and lymphoid hematopoietic progenitors in bone marrow cultures, 2 mainly by ligand-binding-dependent phosphorylation of tyrosine residues located at the cytoplasmic portion of ckit, thereby initiating signal transduction pathways. 3 In normal bone marrow, c-kit is expressed by stem cells, most erythroid and megakaryocytic precursors, a subset of granulocytic and monocytic cells and mature mast cells. [4] [5] [6] In 1994, Pinto et al 7 reported that c-kit is expressed in CD30 þ lymphomas, including most cases of anaplastic large-cell lymphoma (ALCL) and approximately 50% of Hodgkin's disease (HD), but not in other nonHodgkin's lymphomas. Subsequently, c-kit was reported to be expressed and functional in most HD cell lines. 8, 9 However, others 10, 11 have not confirmed these results. In addition, in a preliminary study published as a letter, we could not identify c-kit-positive cases of HD and ALK þ ALCL. 12 Thus, expression and functional status of c-kit in lymphomas remains a controversial issue. Furthermore, expression of c-kit in other CD30-positive lymphomas such as ALK-negative ALCL and cutaneous ALCL, as well as lymphomatoid papulosis, the latter closely related to cutaneous ALCL, is unknown.
Imatinib mesylate (imatinib, STI571, Gleevec s , Novartis Pharma AG, Basel, Switzerland) was first developed as a specific inhibitor of the bcr-abl protein tyrosine kinase 13 and is clinically used for the treatment of patients with chronic myeloid leukemia. 14, 15 Subsequently, imatinib was found to inhibit other receptor tyrosine kinases, including ckit, 16, 17 and was shown to be active against c-kitpositive gastrointestinal stromal tumors. 18 With previous reports of c-kit expression in HD and ALCL having obvious therapeutic implications for imatinib or similar chemotherapeutic agents, and yet at variance with our preliminary results, 12 we decided to assess rigorously for c-kit expression in HD and ALCL cell lines and a large number of CD30 þ lymphomas including HD, systemic ALCL and cutaneous ALCL. We also assessed cases of lymphomatoid papulosis. Since, the effect of imatinib in ALCL cells is unknown, we also assessed viability and proliferation of ALCL cell lines after treatment with imatinib.
Our data show that c-kit is not expressed in HD or ALCL cell lines and is rarely expressed in CD30 þ lymphomas. Only one lymphoma, an ALK-negative case of ALCL, was c-kit-positive. All cases of lymphomatoid papulosis were negative. Treatment of HD and ALCL cell lines with imatinib did not affect viability or proliferation. These findings suggest that c-kit does not appear to be an appropriate target for investigational therapies in patients with HD or ALCL.
Materials and methods

Cell Lines
The panel of cell lines used included five known classical HD cell lines (HD-MYZ, HDLM2, L-428, KM-H2, and L-1236) (purchased from DSMZ, Braunschweig, Germany), two novel classical HD cell lines recently established at our institution (MDA-V and MDA-E), and five ALK-positive ALCL cell lines (Karpas 299, SR-786, SU-DHL-1, JB-6, and TS-G1). The gastrointestinal stromal tumor cell line ST-882 (a gift from Dr J Trent, Houston, TX, USA) and the megakaryoblastic leukemia cell line MO7e (a gift from Dr M Andreeff, Houston, TX, USA) served as positive controls for c-kit expression. The cell lines were maintained in RPMI 1640 medium supplemented with 1% nonessential amino acids, 10% fetal calf serum (Invitrogen Corporation, Grand Island, NY, USA), and 1% streptomycin-penicillin. Cells were incubated at 371C in a humidified atmosphere containing 5% CO 2 . Paraffin-embedded cell blocks of cell pellets fixed in 10% buffered formalin were also prepared.
RNA Extraction and Reverse
Transcription-Polymerase Chain Reaction RNA was extracted using the RNAqueous s kit (Ambion Inc, Austin, TX, USA) according to the manufacturer's instructions. cDNA was synthesized using the Superscriptt First Strand Synthesis System for reverse transcription (RT)-polymerase chain reaction (PCR) (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The quality of cDNA was tested by PCR using primers specific for the 18S cDNA. For RT-PCR amplification of c-kit, we used the following primers: 5 0 -AACGACACGCTGGTCCGCTG-3 0 (forward), and 5 0 -GTACACAGAACTAGACACATC-3 0 (reverse). We also tested another set of primers and conditions as reported by Aldinucci et al.
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Southern Blot Analysis of the RT-PCR Products
Following amplification, 10 ml of RT-PCR products were run on a 1.5%. agarose gel, transferred to Hybond N þ nylon membranes (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA) and hybridized with an internal oligonucleotide, 5 0 -CCCAGAAGTGACCAATTATTCCCT-3 0 . This probe was labeled for 2 h at 371C according to the manufacturer's instructions (Amersham Pharmacia Biotech). After hybridization, the membrane was incubated with detection reagent for 5 min at room temperature, drained, and placed in a film cassette for autoradiography.
Western Blot Analysis
Cells in log-phase growth were collected and lysed at 41C in lysis buffer with appropriate protease and phosphatase inhibitors. Western blot analysis was performed using standard methods and 50 mg of total protein from each cell line. Two commercially available polyclonal antibodies specific for c-kit were used: A4502 (DAKO, Carpinteria, CA, USA), and C-19 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Both antibodies were raised against a peptide from the cytoplasmic C-terminal part of human c-kit.
Flow Cytometry
Cells from all seven HD and one ALCL cell lines (Karpas 299) were analyzed for c-kit expression by flow cytometry with a phycoerythrin-conjugated monoclonal antibody specific for c-kit (clone 104D2, BD Biosciences Pharmingen, San Diego, CA, USA) using standard protocols and a FACScan instrument (Becton Dickinson, San Jose, CA, USA). The MO7e cell line served as a positive control for c-kit expression in these experiments.
Annexin V/propidium iodide (PI) staining was also performed using flow cytometry according to the manufacturer's guidelines. Briefly, 0.5 Â 10 6 cells were washed in ice-cold PBS without Ca 2 þ or Mg 2 þ (Life Technologies). The cells were then resuspended in 100 ml of binding buffer and incubated with 5.0 ml of PI and 2.0 ml of annexin V-fluorescein isothiocynate for 15 min in the dark at room temperature. Flow cytometric analysis was immediately performed using a FACSCalibur Instrument (Becton Dickinson).
Immunohistochemistry c-Kit expression was assessed immunohistochemically in 87 classical HD (66 nodular sclerosis, 21 mixed cellularity), 63 ALCL (30 ALK-positive, 33 ALK-negative), and 15 cutaneous ALCL. We also assessed 18 cases of lymphomatoid papulosis, a disorder closely related to cutaneous ALCL. All lesions were diagnosed at The University of Texas MD Anderson Cancer Center. The histologic diagnoses of the lymphomas were based on criteria specified in the World Health Organization (WHO) classification. 19 The distinction between cutaneous ALCL and lymphomatoid papulosis was based on clinical data.
Full tissue sections and tissue microarrays 20 that included three or four tumor cores were assessed using an immunohistochemical method as described elsewhere. 21 Of the most widely used commercially available antibodies against c-kit, we used the A4502 polyclonal antibody from DAKO, since a recent validation study reported optimal immunohistochemical results and high specificity using this reagent. 22, 23 Full tissue sections obtained from a gastrointestinal stromal tumor were used as a positive control. In addition, occasional monocytes and mast cells seen in many HD and ALCL tumors served as internal positive controls for c-kit expression.
Imatinib Treatment and Proliferation Assay
A panel of cell lines including Karpas 299, SUDHL-1, L-428, HD-LM2, and HD-MyZ were treated in 12-well plates with imatinib using different concentrations of drug (0.05, 0.5, and 5 mM).
11 At 24 and 48 h a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS] was added to each well using the CellTiter 96 s AQ ueous kit (Promega, Madison, WI, USA) according to the manufacturer's instructions and light absorbance was measured using a m Quant spectrophotometer (BIO-TEK Instruments Inc., Winooski, VT, USA). The MTS assay was performed twice and the mean numbers of proliferating and viable cells were calculated at 24 and 48 h after treatment with imatinib.
Results
c-kit RNA Levels in HD and ALCL Cell Lines Table 1 summarizes the results for c-kit expression in HD and ALCL cell lines at the RNA level. Using RT-PCR and a set of primers we designed, all HD and ALCL cell lines were found to be negative for c-kit RNA (Figure 1 ). Southern blot transfer and hybridization using a probe specific for c-kit revealed no bands observed in HD or ALCL cell lines. Only the gastrointestinal stromal tumor cell line (positive control) showed hybridization of appropriately sized products. Figure 1 ). These results were further confirmed by immunohistochemistry using cell blocks prepared from these cell lines and a polyclonal antibody reactive with c-kit c-kit in CD30 þ lymphomas GZ Rassidakis et al (Table 1) . We also studied seven HD and one ALCL (Karpas 299) cell lines using a monoclonal antibody specific for c-kit and flow cytometry immunophenotypic methods; all cell lines were negative (Table 1, Figure 2 ).
c-kit Protein Expression in CD30 þ Lymphomas
Using immunohistochemical methods, c-kit was not expressed in the Hodgkin and Reed-Sternberg (HRS) cells of all 87 classical HD tumors (Figure 3a) . 
Discussion
This report provides in vivo and in vitro evidence that c-kit is not expressed at the RNA or protein level in HD and ALK-positive ALCL cell lines and tumors. In cell lines, we used an RT-PCR method to amplify c-kit mRNA and confirmed the results by Southern blot transfer and hybridization with a c-kit specific probe. We also utilized a variety of methods to assess c-kit protein including flow cytometry, Western blot analysis and immunohistochemical techniques. In 165 CD30 þ lymphomas and 18 cases of lymphomatoid papulosis, we showed c-kit expression using immunohistochemical methods in only one (0.5%) case, an ALK-negative ALCL tumor that showed a typical membranous staining pattern for c-kit (Figure 3c ). The data presented here extend the results of a preliminary study from our institution that included only ALK-positive ALCL tumors and a smaller number of HD tumors. 12 Our findings are also in agreement with two recent reports that demonstrated no evidence of c-kit immunoreactivity in a total of 32 HD tumors. 10, 11 These results and our data are contrary to those of Pinto et al 7 who found c-kit expression in fresh-frozen sections of 11 of 16 ALCL and 11 of 21 HD tumors. Subsequently, the same group reported that five of six HD cell lines expressed functional c-kit receptor. 8 In both studies, the authors used the 17F11 monoclonal antibody that recognizes an extracellular domain of c-kit. The 17F11 antibody was raised by immunization of a Balb/c mouse with leukemic blasts from a patient with acute non-lymphocytic leukemia and was reported to react positively with most leukemic blasts of myeloid, but not lymphoid, lineage. The authors reported that 17F11 specifically recognized the c-kit gene product in NIH-3T3 fibroblasts transfected with the human c-kit gene. 24 However, subsequent functional studies showed that the corresponding epitope of 17F11 was not competing for stem cell factor (SCF), the c-kit ligand-binding site. 25 The 17F11 antibody is no longer commercially available and we could not test its immunoreactivity in this study. Our data, showing absence of c-kit expression in HD and ALCL cell lines, are supported, in part, by a recent preclinical study by Re et al. 11 They reported that only one of six HD cell lines tested, the L-1236 cell line, was positive for c-kit by flow cytometry. We also demonstrate here that treatment with different doses of imatinib did not affect proliferation or viability of two ALCL and three HD cell lines (Figure 4) . Annexin V/7-AAD staining also confirmed that HD and ALCL cells treated with imatinib do not undergo chemotherapy-induced apoptosis ( Figure 5 ). Our data are supported by the results of two other studies. Re et al 11 showed that the proliferation of L-1236 cells was not influenced by stimulation with SCF, anti-SCF antibody, or imatinib. Ergin et al 26 demonstrated that imatinib had only a minimal effect on apoptosis of three ALCL cell lines (Karpas 299, SUPM2, and SU-DHL-1).
The explanation for the remarkable discrepancy between the studies of Pinto et al 7 and Aldinucci and colleagues 8, 9 with our data regarding c-kit expression in HD and ALCL is uncertain. However, a cross reaction of the 17F11 antibody with an unrelated epitope cannot be excluded, since the c-kit in CD30 þ lymphomas GZ Rassidakis et al results obtained using this antibody have not been confirmed using other commercially available antibodies. In addition, independent work from others using immunohistochemical methods with widely used antibodies failed to show c-kit expression in the HRS cells of HD. 10, 11 At the RNA level, Aldinucci et al 8 have reported that c-kit RNA is detected in HD-derived cell lines. We also tested the primers and RT-PCR conditions as described in their study. 8 Although we observed multiple RT-PCR products in ethidium-stained gels using the HD and ALCL cell lines we tested, following Southern blot transfer and hybridization with a specific c-kit probe there was no hybridization (data not shown). Thus, we believe that these RT-PCR products are likely to be nonspecific.
We conclude that c-kit RNA and protein are consistently not expressed in HD and ALK-positive ALCL cell lines and tumors or in cutaneous ALCL tumors and that c-kit is only rarely (o5%) expressed in ALK-negative ALCL tumors. All cases of lymphomatoid papulosis were also negative for c-kit. In addition, imatinib does not seem to be active in HD and ALCL in vitro. These findings suggest that c-kit is probably not an appropriate target for therapeutic agents such as imatinib in the treatment of patients with HD and ALCL.
